TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.
Sinn M, Sinn BV, Treue D, Keilholz U, Damm F, Schmuck R, Lohneis P, Klauschen F, Striefler JK, Bahra M, Bläker H, Bischoff S, Pelzer U, Oettle H, Riess H, Budczies J, Denkert C.
Sinn M, et al. Among authors: pelzer u.
Clin Cancer Res. 2020 Jul 15;26(14):3732-3739. doi: 10.1158/1078-0432.CCR-19-3034. Epub 2020 Mar 31.
Clin Cancer Res. 2020.
PMID: 32234756